Find the best CNRS technologies to boost your innovative project.
30.01.2020
11827-01
06.11.2018
Materials – Coating 07293-01
06.11.2018
Materials – Coating 10581-01
06.11.2018
Chemistry / Environment 08758-01
06.11.2018
11127-01
06.11.2018
Environment and Energy 11107-01
We can guide you through the whole technology transfer process.
Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.
06081-01
DNA replication origins, ORC Ubiquitin-ligase, cancer, orphan diseases
Priority patent application n° EP13305725.7 filed on May 31, 2013, entitled “Protein involved in DNA replication, and modulation of its activity.”
Marcel MECHALI
Philippe COULOMBE
Exclusive or non-exclusive license
Institut de Génétique Humaine (IGH, UPR1142) in Montpellier, France
Although DNA replication is a vital process for cell growth and its mechanism is highly conserved, recent studies also reveal significant diversity in origin structure, assembly of pre-replication complex (pre-RC) and regulation of replication initiation along evolutionary lines.
It is crucial to maintain genomic integrity in eukaryotic cells. During DNA replication, errors in pre-RC assembly often result in substantial changes in the amount of genetic material, which will cause cell death, or transform cells to become malignant tumors.
The first origin recognition complex (ORC) proteins were purified from cell extracts as a heterohexameric complex that specifically binds to origins of DNA replication and the subunits were named Orc1 through Orc6.
The invention is based on the characterization by the inventors of a new protein that physically interacts with the ORC protein complex and that is involved in DNA replication. By a purification process of the ORC protein complex, the inventors have identified a new ORC protein complex partner which has been identified to specifically interact with both ORC1 and LRWD1 proteins. They named this protein ORC Ubiquitin-ligase 1 or Obi1.
The invention relates to this protein or derived proteins as drug and to coumpounds affecting (i.e. inhibiting or activating) the expression or the activity of said protein.
This innovation could be used for diagnosing and treating pathologies involving a deregulation of DNA replication (cancers or rare diseases as Seckel syndrome, Meier-Gorlin syndrome, Majewski osteodysplastic primordial dwarfism type II, etc.)
08.02.2017
Chemistry / Environment, Health / Therapeutic, Medical Diagnostic, Materials – Coating 00957-03
07.06.2016
Health / Therapeutic, Medical Diagnostic 06433-01
05.06.2015
Medical Diagnostic 06100-01
30.01.2020
11827-01
06.11.2018
Materials – Coating 07293-01
06.11.2018
Materials – Coating 10581-01
06.11.2018
Chemistry / Environment 08758-01
06.11.2018
11127-01
06.11.2018
Environment and Energy 11107-01